Minimal change disease laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(16 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Minimal change disease}}
{{Minimal change disease}}
==Laboratory Findings==
{{CMG}}; {{AE}} {{VKG}}
===Blood Work-Up===
*Elevated hematocrit due to volume contraction
*Serum electrolytes may show pesudohyponatremia, defined as low serum sodium levels due to elevated serum lipids
*Hypocalcemia
*Hypovitaminosis D
*Normal/elevated serum creatinine
*Hypoalbuminemia
*Abnormal lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides)
*ANA panel is usually normal
*Complement levels are usually normal


===Urinary Findings===
==Overview==
          Normal  0          false  false  false    EN-US  JA  X-NONE                                                                                                                                                                                                                                                                                                                                                                      24-hour urinary analysis is indicated in the work-up of minimal change disease.
Laboratory findings in minimal change disease include elevated [[hematocrit]], [[pseudohyponatremia]], [[hypocalcemia]], and abnormal lipid panel. Findings of urine analysis include elevated [[urinary specific gravity]], [[proteinuria]] that might reach [[nephrotic]] range, high urinary protein-[[creatinine]] ratio, microscopic [[hematuria]], and lipid-laden cells.
*Elevated urinary specific gravity
*Proteinuria that might reach nephrotic-range
*High urinary protein-creatinine ratio
*Microscopic hematuria
*Lipid-laden cells


===Imaging===                                                                                                                                                                                                                                                                                                                                                                    Imaging in nephrotic syndrome is usually unremarkable.
==Laboratory Findings==
 
===Blood===
===Kidney Biopsy===
* [[Fibrinogen]], factors V and VIII, and [[protein C]] increases and increased risk of thrombosis due to  hypercoagulability.<ref name="pmid279404604">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref><ref name="pmid22344511">{{cite journal |vauthors=Kerlin BA, Ayoob R, Smoyer WE |title=Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease |journal=Clin J Am Soc Nephrol |volume=7 |issue=3 |pages=513–20 |date=March 2012 |pmid=22344511 |pmc=3302669 |doi=10.2215/CJN.10131011 |url=}}</ref>
A kidney biopsy is not routinely performed as soon as nephrotic syndrome is found during lab work-up. According to the National Kidney Foundation (NKF) Kidney Disease – Improve Global Outcomes (KDIGO) guidelines in 2012<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408  }} </ref>, an initial attempt using corticosteroids should be performed before a renal biopsy is performed.
 
====Light Microscopy====
A renal biopsy of minimal change disease shows no abnormalities on light microscopy. Lipid-laden cells may be seen in proximal tubular epithelium. Additional features of focal segmental glomerulosclerosis, such as mesangial prominence, interstitial fibrosis, and tubular atrophy, or glomerular tip lesions of FSGS, may be seen in patients who have complicated disease.<ref name="pmid12704572">{{cite journal| author=D'Agati V| title=Pathologic classification of focal segmental glomerulosclerosis. | journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 2 | pages= 117-34 | pmid=12704572 | doi=10.1053/snep.2003.50012 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12704572  }} </ref> Those with acute renal injury may have histological features of focal flattening of the proximal tubular epithelium.<ref name="pmid12704572">{{cite journal| author=D'Agati V| title=Pathologic classification of focal segmental glomerulosclerosis. | journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 2 | pages= 117-34 | pmid=12704572 | doi=10.1053/snep.2003.50012 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12704572  }} </ref>


====Immunofluorescence====
*Elevated [[hematocrit]] due to volume contraction.<ref name="pmid279404605">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref>
Renal biopsy is often unremarkable under immunofluorescence, with the exception of few cases that stain positively for IgM antibodies and C3.<ref name="pmid12704572">{{cite journal| author=D'Agati V| title=Pathologic classification of focal segmental glomerulosclerosis. | journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 2 | pages= 117-34 | pmid=12704572 | doi=10.1053/snep.2003.50012 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12704572  }} </ref>
*Serum electrolytes may show [[pseudohyponatremia]], defined as low serum sodium levels due to elevated serum lipids.
*[[Hypocalcemia]].
*Hypovitaminosis D.
*Normal/elevated serum [[creatinine]].
*[[Hypoalbuminemia]].
*Abnormal [[lipid profile]] (total [[cholesterol]], [[LDL-C]], [[HDL-C]], [[triglyceride]]s) due to<ref name="pmid279404606">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref>
**Decreased activity of [[lipoprotein lipase]].
**Decreased [[LDL]] receptor activity.
**Increased urinary loss of [[HDL]] and [[antithrombin III]].
*[[IgG]] decreased.
*[[IgA]] is minimally reduced.<ref name="pmid24527245">{{cite journal |vauthors=Oberweis BS, Mattoo A, Wu M, Goldfarb DS |title=Minimal change disease and IgA deposition: separate entities or common pathophysiology? |journal=Case Rep Nephrol |volume=2013 |issue= |pages=268401 |date=2013 |pmid=24527245 |pmc=3914242 |doi=10.1155/2013/268401 |url=}}</ref>
*[[IgM]] is increased.
===Urine===
* 24-hour urinary analysis is indicated in the work-up of [[minimal change disease]].<ref name="pmid27940460">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref><ref name="VivarelliMassella2017">{{cite journal|last1=Vivarelli|first1=Marina|last2=Massella|first2=Laura|last3=Ruggiero|first3=Barbara|last4=Emma|first4=Francesco|title=Minimal Change Disease|journal=Clinical Journal of the American Society of Nephrology|volume=12|issue=2|year=2017|pages=332–345|issn=1555-9041|doi=10.2215/CJN.05000516}}</ref>              


====Electron Microscopy====
*Elevated [[urinary specific gravity]].
Electron-microscopy is required for the diagnosis of minimal change disease. It shows effacement (fusion) of podocytes, which are visceral epithelial cells, with slit-pore membrane obliteration between podocyte foot processes.  However, podocyte effacement is not specific and should not be considered pathognomonic of the disease.<ref name="pmid12704572">{{cite journal|author=D'Agati V| title=Pathologic classification of focal segmental glomerulosclerosis. |journal=Semin Nephrol | year= 2003 | volume= 23 | issue= 2 | pages= 117-34 | pmid=12704572 |doi=10.1053/snep.2003.50012 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12704572  }} </ref>
*[[Proteinuria]] that might reach [[nephrotic]] range.
*High urinary protein-[[creatinine]] ratio.
*Microscopic [[hematuria]].
*Lipid-laden cells.
*Gross [[hematuria]].<ref name="pmid279404602">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref>
*Urinary dipstick showing 3+/4+ [[proteinuria]] (≥300 mg/dl).<ref name="pmid279404603">{{cite journal |vauthors=Vivarelli M, Massella L, Ruggiero B, Emma F |title=Minimal Change Disease |journal=Clin J Am Soc Nephrol |volume=12 |issue=2 |pages=332–345 |date=February 2017 |pmid=27940460 |pmc=5293332 |doi=10.2215/CJN.05000516 |url=}}</ref>
*Urine protein-to-[[creatinine]] ratio >200 mg/mmol.
*Urine [[Protein|proteins]] >3.5 g/d in adults.<ref name="pmid17699450">{{cite journal |vauthors=Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G |title=Adult minimal-change disease: clinical characteristics, treatment, and outcomes |journal=Clin J Am Soc Nephrol |volume=2 |issue=3 |pages=445–53 |date=May 2007 |pmid=17699450 |doi=10.2215/CJN.03531006 |url=}}</ref>
*Increased ''α''2-[[globulin]] and a reduced ''γ''-[[globulin]] fraction.


==References==
==References==
Line 40: Line 42:
{{WS}}
{{WS}}


[[Category:Needs content]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Kidney diseases]]
[[Category:Kidney diseases]]
[[Category:Urology]]
[[Category:Urology]]

Latest revision as of 14:39, 13 June 2018

Minimal Change Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Minimal Change Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Immunohistology

Electron Microscopy

Electrocardiogram

X-ray

Echocardiorgaphy or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Minimal change disease laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Minimal change disease laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Minimal change disease laboratory findings

CDC on Minimal change disease laboratory findings

Minimal change disease laboratory findings in the news

Blogs on Minimal change disease laboratory findings

Directions to Hospitals Treating Minimal change disease

Risk calculators and risk factors for Minimal change disease laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Laboratory findings in minimal change disease include elevated hematocrit, pseudohyponatremia, hypocalcemia, and abnormal lipid panel. Findings of urine analysis include elevated urinary specific gravity, proteinuria that might reach nephrotic range, high urinary protein-creatinine ratio, microscopic hematuria, and lipid-laden cells.

Laboratory Findings

Blood

Urine

References

  1. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  2. ↑ Kerlin BA, Ayoob R, Smoyer WE (March 2012). "Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease". Clin J Am Soc Nephrol. 7 (3): 513–20. doi:10.2215/CJN.10131011. PMC 3302669. PMID 22344511.
  3. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  4. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  5. ↑ Oberweis BS, Mattoo A, Wu M, Goldfarb DS (2013). "Minimal change disease and IgA deposition: separate entities or common pathophysiology?". Case Rep Nephrol. 2013: 268401. doi:10.1155/2013/268401. PMC 3914242. PMID 24527245.
  6. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  7. ↑ Vivarelli, Marina; Massella, Laura; Ruggiero, Barbara; Emma, Francesco (2017). "Minimal Change Disease". Clinical Journal of the American Society of Nephrology. 12 (2): 332–345. doi:10.2215/CJN.05000516. ISSN 1555-9041.
  8. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  9. ↑ Vivarelli M, Massella L, Ruggiero B, Emma F (February 2017). "Minimal Change Disease". Clin J Am Soc Nephrol. 12 (2): 332–345. doi:10.2215/CJN.05000516. PMC 5293332. PMID 27940460.
  10. ↑ Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G (May 2007). "Adult minimal-change disease: clinical characteristics, treatment, and outcomes". Clin J Am Soc Nephrol. 2 (3): 445–53. doi:10.2215/CJN.03531006. PMID 17699450.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Minimal_change_disease_laboratory_findings&oldid=1476547"